Metabolic HealthTirzepatide Lowers BMI by 18.5% in Adolescents With Obesity
A randomized trial suggests tirzepatide can substantially reduce body mass index, a measure of weight relative to height, in adolescents with obesity or overweight and related complications. Researchers assigned 160 adolescents aged 12 to 17 to weekly tirzepatide injections or placebo for 72 weeks, alongside healthy lifestyle support. Average body mass index fell 18.5% with tirzepatide but rose 0.5% with placebo. About 80% receiving tirzepatide achieved at least a 5% reduction, compared with 29% receiving placebo. Digestive side effects were the most common and were usually mild to moderate. These results support further consideration of tirzepatide in adolescent obesity care, but do not establish pediatric approval, lifelong safety, or prevention of future disease. This summary is based only on the abstract, which provides limited safety details.